The SureSelect XT Human Methyl-Seq System was presented by Agilent Technologies last week at the Advances in Genome Biology and Technology meeting in Florida. The Agilent SureSelect XT Methyl-Seq is the first comprehensive DNA methylation discovery system that uses target enrichment.
It enables researchers to analyze more than 3.7 million individual CpG (Cytosine-phosphate-Guanine) sites for their methylation state. Agilent states that the SureSelect XT Human Methyl-Seq System delivers higher throughput and lower costs than whole genome bisulfate sequencing.
“…The assay combines SureSelect, the leading target-enrichment platform, with bisulfite sequencing, the gold standard for DNA methylation research and the first comprehensive discovery system. This enables unprecedented sequence coverage of only the most relevant regions for epigenetic studies, including those associated with a wide range of disorders such as cancer, imprinting disorders, behavioral and mental disorders, and many others….”
More information: SureSelect – How it Works